CVS Health goes in­to the biosim­i­lar mar­ket with new sub­sidiary

CVS Health an­nounced Wednes­day that it launched a busi­ness that will work with drug­mak­ers to com­mer­cial­ize and man­u­fac­ture biosim­i­lars in the US, start­ing with a Hu­mi­ra biosim­i­lar de­vel­oped by San­doz.

San­doz has said it plans to launch Hy­ri­moz in Sep­tem­ber, and now the biosim­i­lar will al­so be made avail­able in the first quar­ter of 2024 un­der the pri­vate la­bel for Cor­davis, the new CVS sub­sidiary. CVS said it ex­pects the biosim­i­lar to cost 80% less than the cur­rent list price for Hu­mi­ra, Ab­b­Vie’s block­buster ther­a­py that lost patent ex­clu­siv­i­ty this year. GoodRx lists the price for two pens of Hu­mi­ra be­tween $6,000 and $7,000 at var­i­ous re­tail­ers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER